Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Shares Outstanding (Diluted Average) (2021 - 2025)

Stoke Therapeutics has reported Shares Outstanding (Diluted Average) over the past 5 years, most recently at $59.2 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 9.65% year-over-year to $59.2 million; the TTM value through Dec 2025 reached $59.2 million, up 9.65%, while the annual FY2025 figure was $59.2 million, 9.65% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $59.2 million at Stoke Therapeutics, down from $60.4 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $60.4 million in Q3 2025 and troughed at $36.7 million in Q4 2021.
  • A 5-year average of $48.0 million and a median of $44.3 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Biggest five-year swings in Shares Outstanding (Diluted Average): grew 5.87% in 2022 and later rose 28.59% in 2024.
  • Year by year, Shares Outstanding (Diluted Average) stood at $36.7 million in 2021, then grew by 5.87% to $38.9 million in 2022, then grew by 13.1% to $44.0 million in 2023, then rose by 22.76% to $54.0 million in 2024, then grew by 9.65% to $59.2 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for STOK at $59.2 million in Q4 2025, $60.4 million in Q3 2025, and $59.7 million in Q2 2025.